NorthWest Biotherapeutics Inc (NWBO)

[Astavakra]

When word gets out to other physicians they will be asking for this.

Yes, and that's why, IMO, a journal targeted to oncologists rather than the general medical community might be preferred. We want to get this information into the hands of the doctors who are going to request and use the vaccine. So, although NEJM is a prestigious almost household name, I believe that Annals of Oncology will have more impact on our target readership. I'm hoping for the Annals. Side note: the external comparator article by Pazdur, et al, appeared in AoO.